Kriengkrai Prasert

Dr. Kriengkrai Prasert

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
KPKriengkrai Prasert
Kriengkrai Prasert
SNSutthichai Nakphook
Sutthichai Nakphook
JKJiraphut Kittiwatanachod
Jiraphut Kittiwatanachod
KSKanlaya Sornwong
Kanlaya Sornwong
SNSuriya Naosri
Suriya Naosri
PPPrabda Praphasiri
Prabda Praphasiri
Background/Objectives: HXP-GPOVac is a locally produced, inactivated Newcastle disease virus-based (NDV-HXP-S) COVID-19 vaccine manufactured in Thailand. This phase II trial compared its safety and immunogenicity with the mRNA vaccine BNT162b2 in adults aged 18–75 years. Methods: In this randomized, double-blind, active-controlled trial registered with the Thai Clinical Trials Registry (TCTR20220819003), 300 participants were assigned 3:1 to receive HXP-GPOVac or BNT162b2 on Days 1 and 29. Solicited adverse events (AEs) were recorded for 7 days after each dose, AEs were summarized through 28 days after each dose, and serious adverse events (SAEs), medically attended AEs (MAAEs), and adverse events of special interest (AESIs) were collected through Day 197. Humoral immunogenicity was assessed by pseudovirus 50% neutralization titers (NT50) and anti-spike IgG concentrations at baseline, Day 29, Day 43, and Day 197. Seroconversion was defined as a ≥4-fold increase from baseline. A predefined subset underwent interferon-γ (IFN-γ) and interleukin-5 (IL-5) ELISpot assays to assess cell-mediated immune responses. The primary immunogenicity analysis assessed non-inferiority of HXP-GPOVac compared with BNT162b2 based on the NT50 geometric mean titer ratio, with a prespecified non-inferiority margin of 0.5. Results: Solicited AEs were predominantly mild and occurred more frequently after the first dose in both groups; one or more solicited local or systemic AEs were reported by 23.7% (95% CI: 18.3–29.8) of HXP-GPOVac recipients and 44.7% (95% CI: 33.3–56.6) of BNT162b2 recipients after the first dose. AEs through 28 days after vaccination and SAEs were uncommon; MAAEs occurred in 17.0% of HXP-GPOVac recipients and 22.4% of BNT162b2 recipients, and none were considered related to vaccination. In the HXP-GPOVac group, NT50 geometric mean titers increased from 5.6 at baseline to 65.5 at Day 29 and 505 at Day 43, declining to 63.6 at Day 197. Anti-spike IgG geometric mean concentrations rose from 7.5 BAU/mL at baseline to 102.7 BAU/mL at Day 29 and 514.6 BAU/mL at Day 43, decreasing to 61.0 BAU/mL at Day 197. BNT162b2 induced higher antibody levels at all time points. The NT50 GMT ratio (HXP-GPOVac/BNT162b2) at Day 43 was 0.51 (95% CI: 0.39–0.67); the lower bound did not exceed the prespecified non-inferiority margin of 0.5, and non-inferiority was not established. Seroconversion rates at Day 43 were 97.6% for HXP-GPOVac and 97.1% for BNT162b2 (neutralizing antibody) and 98.6% and 97.1%, respectively (anti-spike IgG). ELISpot analyses demonstrated increased IFN-γ responses after the second dose without evidence of Th2-dominant skewing. Conclusions: HXP-GPOVac was well tolerated and induced substantial humoral and cellular immune responses, with high seroconversion rates and balanced T-cell polarization. Although absolute antibody levels were lower than those induced by BNT162b2 and the prespecified non-inferiority criterion was not met, these findings support continued evaluation of the inactivated NDV-HXP-S vaccine platform.

15 March 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
MSManash Shrestha
Manash Shrestha
PPPenchan Pradubmook-Sherer
Penchan Pradubmook-Sherer
SPSeung Chun Chun Paek
Seung Chun Chun Paek
KPKriengkrai Prasert
Kriengkrai Prasert
SCSutthinan Chawalchitiporn
Sutthinan Chawalchitiporn
PPPrabda Praphasiri
Prabda Praphasiri
Despite the importance of influenza vaccination for healthcare workers (HCWs), their uptake remains challenging. This study aimed to measure influenza vaccine hesitancy among HCWs in Nakhon Phanom province, Thailand. A representative cross-sectional survey was conducted at six hospitals during August – September 2020 using a self-administered questionnaire. HCWs delaying getting influenza vaccines, accepting but unsure, or refusing with doubts were categorized as hesitant. Those accepting without any doubts were classified as non-hesitant. Vaccine hesitancy determinants were identified by multivariable logistic regression analysis. A total of 338 participants (97%) completed the questionnaires; most were female nurses working at district hospitals without pre-existing chronic medical conditions. Nearly 60% of participants (197/338) exhibited influenza vaccine hesitancy, and significant factors included age above 50 years adjusted odds ratio [aOR] 3.2, 95% CI 1.3-8.5), fair knowledge of influenza/vaccination (aOR 0.4, 95% CI 0.2-0.8), and negative influence of other HCW (High level– aOR 2.3, 95% CI 1.1-4.8; Moderate level- aOR 2.1, 95% CI 1.1-4.4). Imparting updated information to the HCW combined with positive guidance from influential peers may help reduce this hesitancy.

17 September 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
ARAnnette Regan
Annette Regan
RGRadhika Gharpure
Radhika Gharpure
MCMonique Chilver
Monique Chilver
NSNigel Stocks
Nigel Stocks
SGSiobhan St George
Siobhan St George
EAEduardo Azziz-Baumgartner
Eduardo Azziz-Baumgartner
Background: Routine monitoring of seasonal influenza vaccine effectiveness (VE) across multiple countries is essential to understand the performance of seasonal vaccine programs. Methods: Using a test-negative study design, we estimated the effectiveness of the 2023 Southern Hemisphere formulation of the seasonal influenza vaccine in preventing outpatient medically attended influenza-like illness (ILI) in Australia, South Africa, and Thailand. Sentinel surveillance systems identified patients presenting with ILI who were tested by RT-PCR for influenza. VE was estimated as one minus the odds ratio comparing the vaccination status of test-positive cases and test-negative non-cases. Models adjusted for country, patients' age group, sex, underlying medical conditions, and calendar week of symptom onset. We assessed the duration of protection by modeling the effect of the interval between vaccination and symptom onset on influenza status. Results: About 2469 ILI outpatients were identified, including 966 (39%) test-positive cases and 1503 (61%) test-negative non-cases; 78% (n = 750/966) of viruses detected were influenza A; 8% (n = 72/966) of test-positive cases and 29% (n = 439/1503) of test-negative non-cases had received an influenza vaccine. Pooled VE was 68% (95% CI: 57%, 76%) against ILI with any influenza virus, 62% (95% CI: 39%, 76%) against influenza A(H1N1)pdm09, 60% (95% CI: 38%, 75%) against influenza A(H3N2), and 76% (95% CI: 59%, 86%) against influenza B. VE point estimates declined from 82% to 43% when the time from vaccination increased from 14 days to 150 days. Conclusions: The 2023 Southern Hemisphere formulation of seasonal influenza vaccines offered protection against ILI in three countries, underscoring the public health benefits of seasonal influenza vaccination programs.

31 May 2026 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
KPKriengkrai Prasert
Kriengkrai Prasert
PPPrabda Praphasiri
Prabda Praphasiri
DDDarunee Ditsungnoen
Darunee Ditsungnoen
SNSuriya Naosri
Suriya Naosri
SPSiripaporn Phuygun
Siripaporn Phuygun
WBWichan Bhunyakitikorn
Wichan Bhunyakitikorn
Antigenically drifted influenza A(H3N2) subclade K viruses have contributed substantially to influenza burden since 2025, but their clinical severity is less well described. Using sentinel surveillance data from Thailand, we found no significant difference in the adjusted odds of hospitalization among those infected with subclade K versus other influenza viruses (adjusted odds ratio 1.06, 95% CI .67, 1.68). This approach to estimating hospitalization risk for an emerging influenza virus subclade using sentinel surveillance data could serve as a model for conducting future rapid assessments. Summary Using sentinel respiratory surveillance data from Thailand, this paper found no large, significant difference in hospitalization risk for patients infected with influenza A(H3N2) subclade K compared with other influenza viruses.

28 July 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
PPPrabda Praphasiri
Prabda Praphasiri
DDDarunee Ditsungneon
Darunee Ditsungneon
Anusak KerdsinAnusak Kerdsin
Anusak Kerdsin
SNSutthichai Nakphook
Sutthichai Nakphook
JKJiraphut Kittiwatanachod
Jiraphut Kittiwatanachod
KPKriengkrai Prasert
Kriengkrai Prasert
Background/Objectives: Waning immunity after primary COVID-19 vaccination supports evaluation of additional doses. HXP-GPOVac is an egg-based, inactivated Newcastle disease virus (NDV)-vectored vaccine expressing a prefusion-stabilized SARS-CoV-2 HexaPro spike antigen. We evaluated the safety, tolerability, and immunogenicity of a single additional 10 µg dose of HXP-GPOVac administered to adults previously primed with two doses of either HXP-GPOVac or BNT162b2. Methods: Study GPO NDV-HXP-S 203 was an open-label phase II extension enrolling adults (18–75 years) who previously completed a two-dose primary series in Study 202 with either HXP-GPOVac or BNT162b2 (Pfizer–BioNTech; Comirnaty). All participants received a single additional 10 µg intramuscular dose of HXP-GPOVac ≥ 6 months after their second primary dose. Solicited local/systemic adverse events (AEs) were recorded for 7 days, unsolicited AEs through Day 28, and serious AEs (SAEs) and adverse events of special interest (AESIs) throughout follow-up. Neutralizing antibody titers (pseudovirus 50% neutralization titer, NT50) and anti-spike IgG (BAU/mL) were assessed pre-dose (Day 1) and post-vaccination through 12 months; a predefined subset underwent IFN-γ and IL-5 ELISpot. SARS-CoV-2 infection during follow-up was assessed using anti-nucleocapsid (anti-N) IgG. Symptomatic COVID-19 was identified through symptom-reported, symptom-triggered RT-PCR testing; sequencing was performed when feasible. Results: All 219 participants received HXP-GPOVac (167 primed with HXP-GPOVac and 52 with BNT162b2). Any solicited local reaction occurred in 22.2% (37/167) of HXP-GPOVac-primed and 26.9% (14/52) of BNT162b2-primed participants; any solicited systemic reaction occurred in 10.8% (18/167) and 13.5% (7/52), respectively. No vaccine-related unsolicited AEs or AESIs were reported. Three deaths occurred during the 12-month follow-up; one (a sudden cardiac death in an HXP-GPOVac-primed participant) was assessed by the safety medical team as possibly related to vaccination, and two were assessed as not related. Neutralizing antibody GMTs increased from 46.33 at baseline to 1569.04 at Day 15 in HXP-GPOVac-primed participants and from 77.25 to 841.34 in BNT162b2-primed participants; corresponding SCRs were 78.8% and 76.9%. Anti-spike IgG GMCs increased from 48.79 to 1480.14 BAU/mL and from 194.48 to 1547.88 BAU/mL, respectively. Responses declined over time but remained above baseline through 12 months. In the cellular immunity subset, post-vaccination IFN-γ responses increased, with comparatively modest IL-5 responses and no pattern suggestive of Th2 predominance. Conclusions: A single additional dose of HXP-GPOVac administered ≥6 months after primary vaccination with HXP-GPOVac or BNT162b2 was generally well tolerated and elicited robust recall humoral responses, with supportive findings of cellular immunity. Trial registration: Thai Clinical Trials Registry, TCTR20230213001.

18 August 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
SCSutthinan Chawalchitiporn
Sutthinan Chawalchitiporn
PTPichaya Tantiyavarong
Pichaya Tantiyavarong
JKJiraphut Kittiwatanachod
Jiraphut Kittiwatanachod
SNSuriya Naosri
Suriya Naosri
KPKriengkrai Prasert
Kriengkrai Prasert
PPPrabda Praphasiri
Prabda Praphasiri
Background/Objectives: Influenza infection is a major trigger of pneumonia and acute exacerbations among patients with chronic obstructive pulmonary disease (COPD). However, national laboratory-confirmed evidence on influenza vaccine effectiveness (VE) in this high-risk population remains limited. This study aimed to estimate the effectiveness of seasonal influenza vaccination against influenza-associated pneumonia and COPD exacerbations among patients with COPD in Thailand. Methods: We conducted a nationwide retrospective test-negative design study using administrative healthcare data from the National Health Security Office linked with laboratory-confirmed influenza surveillance data between 1 June 2013 and 31 May 2025, covering twelve influenza seasons (2013–2024). COPD-related clinical episodes among patients aged ≥40 years who presented with pneumonia or acute exacerbation of COPD and underwent RT-PCR testing for influenza were included. Modified Poisson regression with cluster-robust standard errors was used to estimate adjusted risk ratios (RRs), and VE was calculated as (1 − adjusted RR) × 100. Results: A total of 606,072 COPD-related clinical episodes were included, of which 192,224 (31.7%) were influenza-positive. The overall adjusted VE against influenza-associated pneumonia was 55.9% (95% CI: 47.3–63.1), while VE against influenza-associated COPD exacerbations was 67.0% (95% CI: 48.8–78.8). VE estimates were broadly similar across age groups and consistent across COPD severity strata. Conclusions: Seasonal influenza vaccination was associated with substantial protection against influenza-associated pneumonia and COPD exacerbations among patients with COPD in Thailand.